5ELI
 
 | | Triggering receptor expressed on myeloid cells 2 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Triggering receptor expressed on myeloid cells 2 | | Authors: | Brett, T.J, Kober, D.L. | | Deposit date: | 2015-11-04 | | Release date: | 2016-12-28 | | Last modified: | 2023-09-27 | | Method: | X-RAY DIFFRACTION (3.0977 Å) | | Cite: | Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms.
Elife, 5, 2016
|
|
1R0D
 | |
6BA9
 | | YbtT - Type II thioesterase from Yersiniabactin NRPS/PKS biosynthetic pathway- S89A mutant | | Descriptor: | Iron aquisition yersiniabactin synthesis enzyme, YbtT | | Authors: | Brett, T.J, Kober, D.L, Ohlemacher, S.I, Henderson, J.P. | | Deposit date: | 2017-10-12 | | Release date: | 2018-10-31 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (1.4 Å) | | Cite: | YbtT is a low-specificity type II thioesterase that maintains production of the metallophore yersiniabactin in pathogenic enterobacteria.
J. Biol. Chem., 293, 2018
|
|
6BA8
 | | YbtT - Type II thioesterase from Yersiniabactin NRPS/PKS biosynthetic pathway | | Descriptor: | Iron aquisition yersiniabactin synthesis enzyme, YbtT | | Authors: | Brett, T.J, Kober, D.L, Ohlemacher, S.I, Henderson, J.P. | | Deposit date: | 2017-10-12 | | Release date: | 2018-10-31 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (1.9 Å) | | Cite: | YbtT is a low-specificity type II thioesterase that maintains production of the metallophore yersiniabactin in pathogenic enterobacteria.
J. Biol. Chem., 293, 2018
|
|
6PYO
 | |
6PYX
 | |
5EKO
 | | Crystal structure of MAPK13 complex with inhibitor | | Descriptor: | 3-(4-methyl-1H-imidazol-1-yl)-N-[4-(pyridin-4-yloxy)phenyl]benzamide, Mitogen-activated protein kinase 13 | | Authors: | Brett, T.J, Miller, C.A, Yurtsever, Z. | | Deposit date: | 2015-11-03 | | Release date: | 2016-07-06 | | Last modified: | 2023-09-27 | | Method: | X-RAY DIFFRACTION (2 Å) | | Cite: | First comprehensive structural and biophysical analysis of MAPK13 inhibitors targeting DFG-in and DFG-out binding modes.
Biochim.Biophys.Acta, 1860, 2016
|
|
5EKN
 | | Crystal structure of MAPK13 complex with inhibitor | | Descriptor: | 1-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)-3-[4-(pyridin-4-ylsulfanyl)phenyl]urea, Mitogen-activated protein kinase 13 | | Authors: | Brett, T.J, Miller, C.A, Yurtsever, Z. | | Deposit date: | 2015-11-03 | | Release date: | 2016-07-06 | | Last modified: | 2023-09-27 | | Method: | X-RAY DIFFRACTION (2.594 Å) | | Cite: | First comprehensive structural and biophysical analysis of MAPK13 inhibitors targeting DFG-in and DFG-out binding modes.
Biochim.Biophys.Acta, 1860, 2016
|
|
1KYD
 | |
1KY6
 | |
1KYF
 | |
1KY7
 | |
1KYU
 | |
3NI0
 | | Crystal Structure of Mouse BST-2/Tetherin Ectodomain | | Descriptor: | Bone marrow stromal antigen 2, ISOPROPYL ALCOHOL | | Authors: | Scheaffer, S.M, Brett, T.J. | | Deposit date: | 2010-06-14 | | Release date: | 2010-11-17 | | Last modified: | 2023-09-06 | | Method: | X-RAY DIFFRACTION (1.601 Å) | | Cite: | Structural and Biophysical Analysis of BST-2/Tetherin Ectodomains Reveals an Evolutionary Conserved Design to Inhibit Virus Release.
J.Biol.Chem., 286, 2011
|
|
4YNO
 | |
4EYM
 | | MAPK13 complex with inhibitor | | Descriptor: | 2-(morpholin-4-yl)-N-[4-(pyridin-4-yloxy)phenyl]pyridine-4-carboxamide, Mitogen-activated protein kinase 13 | | Authors: | Miller, C.A, Brett, T.J. | | Deposit date: | 2012-05-01 | | Release date: | 2012-12-19 | | Last modified: | 2024-02-28 | | Method: | X-RAY DIFFRACTION (2.353 Å) | | Cite: | IL-13-induced airway mucus production is attenuated by MAPK13 inhibition.
J.Clin.Invest., 122, 2012
|
|
4EYJ
 | | MAPK13 Complex with inhibitor | | Descriptor: | 1-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)-3-[4-(pyridin-4-yloxy)phenyl]urea, Mitogen-activated protein kinase 13 | | Authors: | Miller, C.A, Brett, T.J. | | Deposit date: | 2012-05-01 | | Release date: | 2012-12-19 | | Last modified: | 2023-09-13 | | Method: | X-RAY DIFFRACTION (2.102 Å) | | Cite: | IL-13-induced airway mucus production is attenuated by MAPK13 inhibition.
J.Clin.Invest., 122, 2012
|
|
4MYG
 | | MAPK13, active form | | Descriptor: | Mitogen-activated protein kinase 13 | | Authors: | Yurtsever, Z, Brett, T.J, Scheaffer, S.M. | | Deposit date: | 2013-09-27 | | Release date: | 2015-03-25 | | Last modified: | 2023-12-06 | | Method: | X-RAY DIFFRACTION (2.594 Å) | | Cite: | The crystal structure of phosphorylated MAPK13 reveals common structural features and differences in p38 MAPK family activation.
Acta Crystallogr.,Sect.D, 71, 2015
|
|
